Liver transplantation for chronic viral hepatitis

Liver Transplantation and SurgeryVolume 1, Issue 1 p. 30-42 Progress in TransplantationFree Access Liver transplantation for chronic viral hepatitis Teresa L. Wright MD, Corresponding Author Teresa L. Wright MD Department of Veterans Affairs Medical Center and the University of California, San Francisco, CAGastroenterology Unit 111B, Veterans Administration Medical Center, 4150 Clement St, San Francisco, CA 94121Search for more papers by this authorBrian Pereira, Brian Pereira New England Medical Center, Boston, MASearch for more papers by this author Teresa L. Wright MD, Corresponding Author Teresa L. Wright MD Department of Veterans Affairs Medical Center and the University of California, San Francisco, CAGastroenterology Unit 111B, Veterans Administration Medical Center, 4150 Clement St, San Francisco, CA 94121Search for more papers by this authorBrian Pereira, Brian Pereira New England Medical Center, Boston, MASearch for more papers by this author First published: January 1995 https://doi.org/10.1002/lt.500010108Citations: 20AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Todo S, Demetris AJ, Van Thiel DH, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619–626. 10.1002/hep.1840130402 CASPubMedWeb of Science®Google Scholar 2 Samuel D, Bismuth A, Mathieu D, Arulnaden J-L, Reynes M, Benhamou J-P, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813–815. 10.1016/0140-6736(91)92515-4 CASPubMedWeb of Science®Google Scholar 3 O'Grady JG, Smith HM, Davies S, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 1992; 14: 104–111. 10.1016/0168-8278(92)90138-F CASPubMedWeb of Science®Google Scholar 4 Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts J, et al. "Occult" hepatitis B viral infection: An important source of transmission to the liver transplant recipient. Lancet 1994; 343: 142–146. 10.1016/S0140-6736(94)90934-2 CASPubMedWeb of Science®Google Scholar 5 Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–1847. 10.1056/NEJM199312163292503 CASPubMedWeb of Science®Google Scholar 6 Lugassy C, Bernuau J, Thiers V, Kroyaand K, Degott C, Wantzin P, et al. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987; 155: 64–71. 10.1093/infdis/155.1.64 CASPubMedWeb of Science®Google Scholar 7 Yoffe B, Burns DK, Bhatt HS, Combes B. Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection. Hepatology 1990; 12: 187–192. 10.1002/hep.1840120202 CASPubMedWeb of Science®Google Scholar 8 Feray C, Zignegno AL, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49: 1155–1158. 10.1097/00007890-199006000-00025 PubMedWeb of Science®Google Scholar 9 Lavine JE, Lake JR, Ascher NL, Ferrell LD, Ganem D, Wright TL. Persistent hepatitis B virus following interferon alfa therapy and liver transplantation. Gastroenterology 1991; 100: 263–267. 10.1016/0016-5085(91)90611-N CASPubMedWeb of Science®Google Scholar 10 Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJM, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150–157. 10.1002/hep.1840130122 CASPubMedWeb of Science®Google Scholar 11 Benner K, Lee RG, Keeffe EB, Lopez RR, Sasaki AW, Pinson CW. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992; 103: 1307–1312. 10.1016/0016-5085(92)91521-5 PubMedWeb of Science®Google Scholar 12 Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390–1396. 10.1136/gut.33.10.1390 PubMedWeb of Science®Google Scholar 13 Fang JWS, Tung FYT, Davis GL, Dolson DJ, Van Thiel DH, Lau JYN. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus pre-core mutant. Gastroenterology 1993; 105: 901–904. 10.1016/0016-5085(93)90910-5 PubMedWeb of Science®Google Scholar 14 Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13: 90–96. 10.1016/0168-8278(91)90869-D PubMedWeb of Science®Google Scholar 15 Parfrey PS, Forbes RDC, Hutchinson TA, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39: 610–615. 10.1097/00007890-198506000-00007 CASPubMedWeb of Science®Google Scholar 16 Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100: 182–188. 10.1016/0016-5085(91)90599-G CASPubMedWeb of Science®Google Scholar 17 Lam KC, Lai CL, Ng RP, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380–386. 10.1056/NEJM198102123040702 CASPubMedWeb of Science®Google Scholar 18 Tur-Kapsa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627–1631. 10.1073/pnas.83.6.1627 PubMedWeb of Science®Google Scholar 19 Pirson Y, Alexandre GPJ, van Ypersele de Strihou C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296: 194–196. 10.1056/NEJM197701272960404 CASPubMedWeb of Science®Google Scholar 20 Peters M, Vierling J, Gershwin ME, Milich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology 1991; 13: 977–994. 10.1002/hep.1840130529 PubMedWeb of Science®Google Scholar 21 Wright TL. Cytomegaloviral infection and vanishing bile duct syndrome. Culprit or innocent bystander?. Hepatology 1992; 16: 494–496. 10.1002/hep.1840160231 CASPubMedWeb of Science®Google Scholar 22 Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, et al. Evolution of hepatitis B virus liver disease after hepatic replacement: practical and theoretical considerations. Am J Pathol 1991; 137: 667–676. Web of Science®Google Scholar 23 Missale G, Brems JJ, Takiff H, Pockros PJ, Chisari FV. Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after transplantation. Hepatology 1993; 18: 491–496. 10.1002/hep.1840180304 CASPubMedWeb of Science®Google Scholar 24 Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145–1156. 10.1016/0092-8674(89)90770-8 CASPubMedWeb of Science®Google Scholar 25 Persing DH, Varmus HE, Ganem D. Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 1986; 234: 1388–1391. 10.1126/science.3787251 CASPubMedWeb of Science®Google Scholar 26 Lau JYN, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJM, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956–962. 10.1016/0016-5085(92)90182-X PubMedWeb of Science®Google Scholar 27 Rakela J, Wooten RS, Batts KP, Perkins JD, Taswell HF, Krom RA. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 1989; 64: 429–432. 10.1016/S0025-6196(12)65733-4 CASPubMedWeb of Science®Google Scholar 28 Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic HBV. Gastroenterology 1993; 104: 1116–1121. 10.1016/0016-5085(93)90281-G PubMedWeb of Science®Google Scholar 29 Marcellin P, Samuel D, Areias J, Loriot M-A, Arulnaden J-L, Gigou M, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6–12. 10.1002/hep.1840190103 PubMedWeb of Science®Google Scholar 30 Lauchart W, Muller R, Pichlmayr R. Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 2387–2389. CASPubMedWeb of Science®Google Scholar 31 Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 4051–4053. CASPubMedWeb of Science®Google Scholar 32 McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15: 757–766. 10.1002/hep.1840150503 CASPubMedWeb of Science®Google Scholar 33 Wright HI, Gavaler JS, Van Thiel DH. Preliminary experience with a-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121–124. 10.1097/00007890-199201000-00023 PubMedWeb of Science®Google Scholar 34 Chossegros P, Pouteil-Noble C, Causse X, Pouyet M, Touraine JL, Trepo C. Gancylcovir is an effective antiviral agent for posttransplantation chronic HBV infections but maintenance therapy is required. J Hepatol 1992; 16 [supplement 1]: S9. Google Scholar 35 Gish RG, Imperial JI, Esquivel CO, Keeffe EB. Ganciclovir treatment of severe hepatitis B virus (HBV) infection [abstract]. Gastroenterology 1993; 104: A908. Google Scholar 36 Marcellin P, Samuel D, Loriot MA, Areias J, Bismuth H, Benhamou JP. Anti-viral effect of adenine arabinoside monophosphate (ARA-AMP) in patients with recurrence of hepatitis B virus (HBV) infection after liver transplantation [abstract]. Hepatology 1990; 12: 966. Web of Science®Google Scholar 37 Rizzetto M, Macagno S, Chiaberge E, Verme G, Negro F, Marinucci G, et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 2: 469–471. 10.1016/S0140-6736(87)91789-2 CASPubMedWeb of Science®Google Scholar 38 Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101: 1649–1655. 10.1016/0016-5085(91)90404-9 CASPubMedWeb of Science®Google Scholar 39 Mason WS, Taylor JM. Liver transplantation: A model for the transmission of hepatitis delta virus. Gastroenterology 1991; 101: 1741–1743. CASPubMedWeb of Science®Google Scholar 40 David E, Rahier J, Pucci A, Camby P, Scevens M, Salizzoni M, et al. Recurrence of hepatitis D (delta) in liver transplants: histopathological aspects. Gastroenterology 1993; 104: 1122–1128. 10.1016/0016-5085(93)90282-H CASPubMedWeb of Science®Google Scholar 41 Samuel D, Zignego AL, Arulnaden JL, David MF, Gigou M, Feray C, et al. Liver transplantation for post hepatitis delta cirrhosis. Hepatology 1992; 16: 45A. Google Scholar 42 Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88–94. 10.1056/NEJM199401133300202 CASPubMedWeb of Science®Google Scholar 43 Hopf U, Neuhaus P, Lobeck H, König V, Küther S, Bauditz J, et al. Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-a. J Hepatol 1991: 13: 339–346. 10.1016/0168-8278(91)90078-P PubMedWeb of Science®Google Scholar 44 Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–322. 10.1016/0016-5085(92)91129-R CASPubMedWeb of Science®Google Scholar 45 Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. Natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905. 10.1056/NEJM199212313272702 PubMedWeb of Science®Google Scholar 46 Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. N Engl J Med 1992; 327: 1906–1911. 10.1056/NEJM199212313272703 PubMedWeb of Science®Google Scholar 47 Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675. 10.1002/hep.1840120409 CASPubMedWeb of Science®Google Scholar 48 Martin P, Munoz SJ, Di Biscegie AM, Rubin R, Waggoner JG, Armenti VT, Moritz MJ, Jarrell BE, Maddrey WC. Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 1991; 13: 719–721. 10.1002/hep.1840130418 CASPubMedWeb of Science®Google Scholar 49 Gretch DR, Dela Rosa C, Perkins J, Corey L, Carrithers R. HCV infection in liver transplant recipients: chronic reinfection is universal, de novo acquisition rare. Hepatology 1992; 16: 45A [abstract]. Google Scholar 50 Hsu HH, Wright TL, Tsao SC, Combs C, Donets M, Feinstone SM, Greenberg HB. Attenuated antibody response to hepatitis C virus after liver transplantation. Am J Gastroenterol 1994; 89: 1109–1174. PubMedWeb of Science®Google Scholar 51 Lok ASF, Chien D, Choo Q-L, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497–502. 10.1002/hep.1840180305 PubMedWeb of Science®Google Scholar 52 Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Ascher NL, et al. Quantitation of Hepatitis C Virus RNA in Liver Transplant Recipients. Gastroenterology 1994; 106: 994–999. 10.1016/0016-5085(94)90759-5 CASPubMedWeb of Science®Google Scholar 53 Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361–1365. 10.1172/JCI115723 PubMedWeb of Science®Google Scholar 54 Shiffman ML, Contos MJ, Luketic VA, Sonyal AJ, Purdum PP, Mills S, et al. Biochemical and histological evaluation of recurrent hepatitis C following orthotopic liver transplantation. Transplantation 1994; 57: 526–532. 10.1097/00007890-199402000-00009 CASPubMedWeb of Science®Google Scholar 55 Nakleh RE, Schwarzenberg SJ, Bloomer J, Payne W, Snover DC. The pathology of liver allografts surviving longer than one year. Hepatology 1989; 11: 465–470. 10.1002/hep.1840110318 PubMedWeb of Science®Google Scholar 56 Shah G, Demetris AJ, Gavaler JS, Lewis JH, Todo S, Starzl TE, et al. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 1992; 103: 323–329. 10.1016/0016-5085(92)91130-V PubMedWeb of Science®Google Scholar 57 Poterucha J, Rakela J, Lumeng L, Lee C-H, Taswell HF, Wiesner RH. Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction. Hepatology 1992; 15: 42–45. 10.1002/hep.1840150109 PubMedWeb of Science®Google Scholar 58 Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454–460. 10.1056/NEJM199108153250702 CASPubMedWeb of Science®Google Scholar 59 Pereira BJG, Wright TL, Schmid CH, Bryan CF, Cheung RC, Cooper ES, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: A U.S. national collaborative study. Kidney International, In Press. Google Scholar 60 Debure A, Degos F, Pol S, Degott C, Carnot F, Lugassy C, Lacombe M, Kreis H. Liver diseases and hepatic complications in renal transplant patients. Adv Nephro 1988; 17: 375–400. CASPubMedGoogle Scholar 61 Klauser R, Franz M, Traindi O, Pidlich J, Hay U, Watschinger B, et al. Hepatitis C antibody in renal transplant patients. Transplant Proc 1992; 24: 286–288. CASPubMedWeb of Science®Google Scholar 62 Pereira BJG, Wright TL, Schmid C, Lipkowitz GA, Shapiro ME, Milford E, et al. Comparative risk of post-transplantation liver disease, graft and patient survival in kidney recipients with and without pretransplantation anti-HCV [abstract]. Am Soc Transplant Physicians 1994; A82. Google Scholar 63 Lau JYN, Davis GL, Brunson ME, Quian K-P, Lin H-J, Quan S, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18: 1027–1031. 10.1002/hep.1840180502 PubMedWeb of Science®Google Scholar 64 Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Pathology of hepatitis C viral infection in liver transplant recipients. Hepatology 1992; 16: 865–876. 10.1002/hep.1840160403 PubMedWeb of Science®Google Scholar 65 Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1991; 341: 1501–1504. 10.1016/0140-6736(93)90635-T PubMedWeb of Science®Google Scholar 66 Krawczynski K, Beach M, Bradley DW, Meeks E, Spelbring JE. Immunosuppression and pathogenetic studies of acute hepatitis C virus (HCV) infection in chimpanzees. Hepatology 1992; 16: 345A [abstract]. Google Scholar 67 Lim HL, Lau GKK, Davis GL, Dolson DJ, Lau JYN. Cholestatic hepatitis leading to hepatic failure in a patient with organ transmitted hepatitis C virus infection. Gastroenterology 1991; 106: 248–251. PubMedWeb of Science®Google Scholar 68 Feray C, Gigou M, Samuel D, Okamoto H, Reynes M, David MF, et al. Direct evidence for a more pathogenic effect of HCV type II: the model of liver transplantation. J Hepatol 1993; 18 (Suppl): S3. Google Scholar 69 Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon alpha therapy for hepatitis C virus infection following liver transplantation. Hepatology 1994; 20: 773–779. 10.1002/hep.1840200402 PubMedWeb of Science®Google Scholar 70 Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, Winkle S, Herrin JT, Black PH, Russell PS, Hirsch MS. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N Engl J Med 1979; 300: 1345–1349. 10.1056/NEJM197906143002401 CASPubMedWeb of Science®Google Scholar 71 Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988; 45: 402–405. 10.1097/00007890-198802000-00031 PubMedWeb of Science®Google Scholar Citing Literature Volume1, Issue1January 1995Pages 30-42 ReferencesRelatedInformation